CN110225752B - 用作gpr120调节器的单环化合物 - Google Patents
用作gpr120调节器的单环化合物 Download PDFInfo
- Publication number
- CN110225752B CN110225752B CN201780068713.3A CN201780068713A CN110225752B CN 110225752 B CN110225752 B CN 110225752B CN 201780068713 A CN201780068713 A CN 201780068713A CN 110225752 B CN110225752 B CN 110225752B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- lcms
- esi
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393616P | 2016-09-12 | 2016-09-12 | |
| US62/393,616 | 2016-09-12 | ||
| PCT/US2017/050956 WO2018049324A1 (en) | 2016-09-12 | 2017-09-11 | Monocyclic compounds useful as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110225752A CN110225752A (zh) | 2019-09-10 |
| CN110225752B true CN110225752B (zh) | 2023-05-05 |
Family
ID=61562455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780068713.3A Active CN110225752B (zh) | 2016-09-12 | 2017-09-11 | 用作gpr120调节器的单环化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10800773B2 (enExample) |
| EP (1) | EP3509587B1 (enExample) |
| JP (1) | JP7086942B2 (enExample) |
| KR (1) | KR102537985B1 (enExample) |
| CN (1) | CN110225752B (enExample) |
| CA (1) | CA3041033A1 (enExample) |
| WO (1) | WO2018049324A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7065081B2 (ja) | 2016-09-12 | 2022-05-11 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な二環式化合物 |
| CN110225752B (zh) | 2016-09-12 | 2023-05-05 | 整体健康 | 用作gpr120调节器的单环化合物 |
| AU2019255363A1 (en) * | 2018-04-20 | 2020-11-05 | Krish Biotech Research Private Limited | Method of treatment of non-alcoholic steatohepatitis, nash |
| US11142525B2 (en) * | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
| CR20220548A (es) | 2020-05-01 | 2022-12-12 | Pfizer | Compuestos de azalactama como inhibidores de hpk1 |
| PH12022553016A1 (en) * | 2020-05-08 | 2024-05-13 | Georgiamune Inc | Akt3 modulators |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110312976A1 (en) * | 2009-03-11 | 2011-12-22 | Msd K.K. | Novel isoindolin-1-one derivative |
| JP2014533736A (ja) * | 2011-11-30 | 2014-12-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規二環式ジヒドロイソキノリン−１−オン誘導体 |
| WO2014209034A1 (en) * | 2013-06-27 | 2014-12-31 | Lg Life Sciences Ltd. | Biaryl derivatives as gpr120 agonists |
| US20150274672A1 (en) * | 2012-10-11 | 2015-10-01 | Merck Sharp & Dohme Corp. | Substituted spiropiperidinyl compounds useful as gpr120 agonists |
| JP2016141618A (ja) * | 2015-01-29 | 2016-08-08 | 国立大学法人金沢大学 | 脱水縮合剤 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2735225A (en) * | 1956-02-21 | Table ix p petri dish tests with x-phthalimido- | ||
| DE2253251A1 (de) | 1972-10-30 | 1974-05-09 | Thomae Gmbh Dr K | Neue phthalimido-sulfonylharnstoffe |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4165435A (en) * | 1976-06-25 | 1979-08-21 | Ciba-Geigy Corporation | Fire retardant s-triazine derivatives |
| DE3474547D1 (en) | 1983-12-02 | 1988-11-17 | Shell Int Research | Diphenyl ether herbicides |
| FR2659327A1 (fr) | 1990-03-08 | 1991-09-13 | Centre Nat Rech Scient | Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5350761A (en) | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| EP0526402B1 (en) | 1991-07-30 | 1998-01-21 | Novartis AG | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors |
| TW219935B (enExample) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| HUP9902455A3 (en) * | 1996-03-29 | 2000-06-28 | Pfizer | 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them |
| US6716836B2 (en) | 2001-03-22 | 2004-04-06 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| EP1688138A4 (en) | 2003-11-26 | 2008-01-16 | Takeda Pharmaceutical | AGENT FOR REGULATING THE FUNCTION OF A RECEIVER |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| JP5405120B2 (ja) | 2006-12-01 | 2014-02-05 | Ｍｓｄ株式会社 | 新規フェニル−イソキサゾール−３−オール誘導体 |
| RU2455302C2 (ru) | 2006-12-27 | 2012-07-10 | Санофи-Авентис | ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ |
| US8394841B2 (en) | 2007-02-22 | 2013-03-12 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
| EP2121675A1 (en) | 2007-02-22 | 2009-11-25 | Irm Llc | Thiazole derivatives as modulators of g protein-coupled receptors |
| WO2008139987A1 (ja) | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | Ｇタンパク質共役型レセプタ－作動剤 |
| WO2009014100A1 (ja) | 2007-07-20 | 2009-01-29 | Chugai Seiyaku Kabushiki Kaisha | ｐ２７蛋白質誘導剤 |
| CA2725316A1 (en) | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| AU2009307656B2 (en) | 2008-10-21 | 2015-07-02 | Cymabay Therapeutics, Inc. | Aryl GPR120 receptor agonists and uses thereof |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| CA2801182A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
| WO2013139341A1 (en) | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| KR101942752B1 (ko) | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| JP2016505550A (ja) | 2012-12-03 | 2016-02-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換トリアゾール及びイミダゾール化合物 |
| EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| PL2970157T3 (pl) | 2013-03-14 | 2019-02-28 | Janssen Pharmaceutica Nv | Benzo-skondensowane heterocykliczne pochodne przydatne jako agonisty gpr120 |
| AU2014244474B2 (en) | 2013-03-14 | 2018-04-26 | Bristol-Myers Squibb Company | Bicyclo [2.2.1] acid GPR120 modulators |
| CA2905729C (en) | 2013-03-14 | 2021-11-09 | Janssen Pharmaceutica Nv | Bicyclic pyrrole derivatives useful as agonists of gpr120 |
| ES2690145T3 (es) | 2013-03-14 | 2018-11-19 | Janssen Pharmaceutica Nv | Agonistas de GPR120 para el tratamiento de diabetes de tipo 2 |
| US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| AR099937A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| DK3140296T3 (en) | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| DK3186241T3 (da) | 2014-08-29 | 2021-01-11 | Chdi Foundation Inc | Prober til billeddannelse af huntington-protein |
| LT3365334T (lt) | 2015-10-21 | 2024-09-10 | Otsuka Pharmaceutical Co., Ltd. | Benzolaktamo junginiai kaip baltymų kinazės inhibitoriai |
| JP7065081B2 (ja) | 2016-09-12 | 2022-05-11 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な二環式化合物 |
| CN110225752B (zh) * | 2016-09-12 | 2023-05-05 | 整体健康 | 用作gpr120调节器的单环化合物 |
-
2017
- 2017-09-11 CN CN201780068713.3A patent/CN110225752B/zh active Active
- 2017-09-11 WO PCT/US2017/050956 patent/WO2018049324A1/en not_active Ceased
- 2017-09-11 EP EP17849719.4A patent/EP3509587B1/en active Active
- 2017-09-11 JP JP2019513935A patent/JP7086942B2/ja active Active
- 2017-09-11 CA CA3041033A patent/CA3041033A1/en active Pending
- 2017-09-11 KR KR1020197010269A patent/KR102537985B1/ko active Active
- 2017-09-11 US US16/331,916 patent/US10800773B2/en active Active
-
2020
- 2020-08-20 US US16/998,660 patent/US11548886B2/en active Active
-
2022
- 2022-10-03 US US17/959,064 patent/US12116362B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110312976A1 (en) * | 2009-03-11 | 2011-12-22 | Msd K.K. | Novel isoindolin-1-one derivative |
| JP2014533736A (ja) * | 2011-11-30 | 2014-12-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規二環式ジヒドロイソキノリン−１−オン誘導体 |
| US20150274672A1 (en) * | 2012-10-11 | 2015-10-01 | Merck Sharp & Dohme Corp. | Substituted spiropiperidinyl compounds useful as gpr120 agonists |
| WO2014209034A1 (en) * | 2013-06-27 | 2014-12-31 | Lg Life Sciences Ltd. | Biaryl derivatives as gpr120 agonists |
| JP2016141618A (ja) * | 2015-01-29 | 2016-08-08 | 国立大学法人金沢大学 | 脱水縮合剤 |
Non-Patent Citations (5)
| Title |
|---|
| "Synthesis and structural investigation of N-pyridyl-1, 3-dihydroxyisoindolines";Jasim Al-Rawi等;《Asian Journal of Chemistry》;19910131;第3卷(第1期);第30-37页，尤其是第30-31页化合物2部分 * |
| "Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials";Neil R. Norcross等;《Journal of Medicinal Chemistry》;20160617;第6101-6120页，尤其是 * |
| RN：1334634-35-3;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20111007 * |
| RN：1440520-62-6;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20130624 * |
| RN：1935530-23-6;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20160620 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3509587A4 (en) | 2020-03-11 |
| US10800773B2 (en) | 2020-10-13 |
| CN110225752A (zh) | 2019-09-10 |
| JP2019530674A (ja) | 2019-10-24 |
| EP3509587B1 (en) | 2023-12-06 |
| JP7086942B2 (ja) | 2022-06-20 |
| KR102537985B1 (ko) | 2023-05-30 |
| KR20190067174A (ko) | 2019-06-14 |
| WO2018049324A1 (en) | 2018-03-15 |
| CA3041033A1 (en) | 2018-03-15 |
| EP3509587C0 (en) | 2023-12-06 |
| EP3509587A1 (en) | 2019-07-17 |
| US20190202821A1 (en) | 2019-07-04 |
| US12116362B2 (en) | 2024-10-15 |
| US20230183231A1 (en) | 2023-06-15 |
| US11548886B2 (en) | 2023-01-10 |
| US20210101896A1 (en) | 2021-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110225752B (zh) | 用作gpr120调节器的单环化合物 | |
| US11919891B2 (en) | Bicyclic compounds useful as GPR120 modulators | |
| US11447453B2 (en) | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | |
| JP4667867B2 (ja) | 置換フロ［２，３−ｂ］ピリジン誘導体 | |
| US20070149547A1 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| JP2009533410A (ja) | Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体 | |
| US10369146B2 (en) | Phenyl linked quinolinyl modulators of RORγt | |
| JP4092732B2 (ja) | ブラジキニン作動薬としてのキノリンおよびベンズイミダゾール誘導体 | |
| CN116438174B (zh) | 化合物及其作为mif抑制剂的用途 | |
| CA3041038C (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005332B (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005332A (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005335B (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005335A (en) | Bicyclic compounds useful as gpr120 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200909 Address after: Massachusetts, USA Applicant after: Overall health Address before: California, USA Applicant before: NUMERATE, Inc. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |